RSS-Feed abonnieren
DOI: 10.1055/a-1516-2471
State of the Art: Therapie mit Statinen
State of the Art: Statin Therapy
Im Jahr 2020 wurden hierzulande 2,7 Milliarden Statin-Tabletten verordnet, das entspricht bei täglicher Einnahme 7,6 Millionen Menschen in Deutschland [1]. Daher hat jeder Internist oder Allgemeinmediziner täglich mit Statin-Verschreibungen zu tun. Die vorliegende Übersichtsarbeit fasst die aktuelle Datenlage zur klinischen Pharmakologie und Wirksamkeit sowie zu Nebenwirkungen und speziellen Therapie-Situationen zusammen.
Abstract
This review summarizes the pharmacology and clinical use of HMG-CoA reductase inhibitors, statins. LDL-Cholesterol lowering with statins reduces atherosclerotic cardiovascular risk by approx. one quater per year of treatment. The efficacy and safety of statins are demonstrated by randomized trials irrespective of the patient’s age. The synthetic statins, rosuvastatin and atorvastatin, are superior with regard to LDL-C lowering, half-life and drug-interactions compared to the older statins such as simvastatin. Modern lipid lowering therapy uses individualized statin-based combination therapies.
Schlüsselwörter
Statine - HMG-CoA-Reduktase - Pharmakologie - pleiotrope Effekte - Statin-IntoleranzPublikationsverlauf
Artikel online veröffentlicht:
06. Dezember 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Schwabe U, Ludwig WD. Hrsg Arzneiverordnungsreport 2020. 1. Aufl.. Berlin: Springer; 2020
- 2 Custodis F, Laufs U. [LDL-Cholesterol – Is there an “LDL hypothesis”?]. Dtsch Med Wochenschr 2015; 140: 761-764
- 3 Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res 2017; 120: 229-243
- 4 Williams JK, Sukhova GK, Herrington DM. et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-691
- 5 Eschenhagen T, Laufs U. Statins Do More Than Lower Cholesterol-Depending on What You Eat?. Circulation 2021; 143: 1793-1796
- 6 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
- 7 Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013; 310: 2451-2452
- 8 Wiegman A, Gidding SS, Watts GF. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-2437
- 9 Gencer B, Marston NA, Im K. et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020; 396: 1637-1643
- 10 Orkaby AR, Driver JA, Ho YL. et al. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. JAMA 2020; 324: 68-78
- 11 Giral P, Neumann A, Weill A. et al. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 2019; 40: 3516-3525
- 12 Laufs U, Scharnagl H, Halle M. et al. Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int 2015; 112: 748-755
- 13 Wood FA, Howard JP, Finegold JA. et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med 2020; 383: 2182-2184
- 14 Stroes ES, Thompson PD, Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-1022